Aim: To examine the effect of selenium (Se) adjuvant therapy on external respiration function (ERF) and quality of life (QOL) in bronchial asthma (BA) patients.
Material and methods: 26 patients with BA received standard therapy and adjuvant 200 mcg/day selenium (SelenoPRECISE, PharmaNord, Denmark) for 16 weeks. ERF was estimated by FEV1 and FVC, QOF--by the response to Juniper Adult Asthma Quality of life Short Questionnaire (AQLQ-S) at initiation and end of the study. Difference with the baseline was assessed using Paired Samples T-Test, SPSS 14.0.
Results: Paired-samples T-test showed that FVC increased significantly from 76.5 +/- 23.8% to 81.8 +/- 23.2% (p = 0.015). FEV1 showed a significant increase from 62.3 +/- 29.6% to 67.7 +/- 28.1% (p = 0.018). Total AQLQ score elevated from 3.25 to 4.71 (p = 0.01).
Conclusion: Correction of Se deficiency in BA patients on standard therapy improves ERF and BA-related QOL. Mechanisms of a protective Se action are involved in antioxidant defense by means of Se participation in enzymatic detoxication of peroxides and a stabilizing effect on biomembranes.